Alterity Therapeutics Limited (ATHE)
NASDAQ: ATHE · Real-Time Price · USD
3.510
-0.010 (-0.28%)
At close: Nov 21, 2025, 4:00 PM EST
3.620
+0.110 (3.13%)
After-hours: Nov 21, 2025, 7:37 PM EST
Alterity Therapeutics Employees
Alterity Therapeutics had 9 employees as of June 30, 2025. The number of employees decreased by 1 or -10.00% compared to the previous year.
Employees
9
Change (1Y)
-1
Growth (1Y)
-10.00%
Revenue / Employee
$396,200
Profits / Employee
-$884,914
Market Cap
63.01M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 9 | -1 | -10.00% |
| Jun 30, 2024 | 10 | -1 | -9.09% |
| Jun 30, 2023 | 11 | -1 | -8.33% |
| Jun 30, 2022 | 12 | 1 | 9.09% |
| Jun 30, 2021 | 11 | -1 | -8.33% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ATHE News
- 10 days ago - Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference - GlobeNewsWire
- 22 days ago - Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report - GlobeNewsWire
- 6 weeks ago - Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson's Disease and Movement Disorders - GlobeNewsWire
- 7 weeks ago - Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson's Disease and Movement Disorders - GlobeNewsWire
- 2 months ago - Alterity Therapeutics Raises A$20.0 million in Strategic Placement - GlobeNewsWire
- 2 months ago - Alterity Therapeutics to Present at the Biotech Showcase - GlobeNewsWire
- 4 months ago - Appendix 4C – Q4 FY25 Quarterly Cash Flow Report - GlobeNewsWire
- 4 months ago - Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy - GlobeNewsWire